Folgen
Yuanwang Pan
Yuanwang Pan
Amgen
Bestätigte E-Mail-Adresse bei nyulangone.org - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex
C Rauskolb, S Sun, G Sun, Y Pan, KD Irvine
Cell 158 (1), 143-156, 2014
3752014
CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer
H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ...
Cancer cell 37 (1), 37-54. e9, 2020
1802020
Differential growth triggers mechanical feedback that elevates Hippo signaling
Y Pan, I Heemskerk, C Ibar, BI Shraiman, KD Irvine
Proceedings of the National Academy of Sciences 113 (45), E6974-E6983, 2016
1532016
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
J Deng, A Thennavan, I Dolgalev, T Chen, J Li, A Marzio, JT Poirier, ...
Nature cancer 2 (5), 503-514, 2021
892021
Squamous cell lung cancer: Current landscape and future therapeutic options
SCM Lau, Y Pan, V Velcheti, KK Wong
Cancer Cell 40 (11), 1279-1293, 2022
662022
Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy
J Hai, H Zhang, J Zhou, Z Wu, T Chen, E Papadopoulos, CM Dowling, ...
Clinical Cancer Research 26 (13), 3431-3442, 2020
592020
The dynamics of Hippo signaling during Drosophila wing development
Y Pan, H Alégot, C Rauskolb, KD Irvine
Development 145 (20), dev165712, 2018
472018
Recent advances in preclinical models for lung squamous cell carcinoma
Y Pan, H Han, KE Labbe, H Zhang, KK Wong
Oncogene 40 (16), 2817-2829, 2021
442021
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng, KH Tang, S Cao, ...
Cancer research 81 (20), 5311-5324, 2021
432021
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Y Pan, H Han, H Hu, H Wang, Y Song, Y Hao, X Tong, AS Patel, ...
Cancer cell 41 (1), 88-105. e8, 2023
362023
Functional identification of a novel 14-3-3 epsilon splicing variant suggests dimerization is not necessary for 14-3-3 epsilon to inhibit UV-induced apoptosis
D Han, G Ye, T Liu, C Chen, X Yang, B Wan, Y Pan, L Yu
Biochemical and Biophysical Research Communications 396 (2), 401-406, 2010
302010
Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer
F Li, WL Ng, TA Luster, H Hu, VO Sviderskiy, CM Dowling, ...
Cancer research 80 (17), 3556-3567, 2020
242020
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
Y Pan, Y Hao, H Han, T Chen, H Ding, KE Labbe, E Shum, K Guidry, H Hu, ...
Journal for immunotherapy of cancer 10 (9), 2022
92022
Near-infrared nuclear markers for Drosophila imaging
Y Pan, C Rauskolb, KD Irvine
Micropublication Biology 2022, 2022
12022
Transiently secretory expression of DsRed driven by sericin promoter with the signal peptide sequence of fibroin H chain of Bombyx mori.
PY Peng Yun, PYW Pan YuanWang, QYY Qian YanYan, ...
12009
Therapeutic targeting of kmt2d mutant lung squamous cell carcinoma through rtk-ras signaling inhibition
K Wong, Y Pan, H Han, H Zhang
US Patent App. 17/935,915, 2023
2023
1661P Antitumor efficacy and immune profiling of the mouse ortholog of nemvaleukin alfa, a novel engineered IL-2 fusion protein, in an orthotopic mouse model of small cell lung …
Y Pan, H Zhang, T Chen, H Ding, H Han, C Almonte, KE Labbe, S Nguyen, ...
Annals of Oncology 32, S1169, 2021
2021
Overcome LKB1 mutated cancer resistance to anti-PD1 treatment
J Deng, A Thennavan, Y Pan, I Dolgalev, T Chen, H Silver, M Harris, ...
Cancer Research 79 (13_Supplement), 3223-3223, 2019
2019
Mechanical Control of Tissue Growth through Hippo Signaling
Y Pan
Rutgers The State University of New Jersey, School of Graduate Studies, 2018
2018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–19